Granulocyte macrophage colony-stimulating factor
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Granulocyte macrophage colony-stimulating factor
| |
| Systematic (IUPAC) name | |
| Human granulocyte macrophage colony stimulating factor | |
| Identifiers | |
| CAS number | |
| ATC code | L03 |
| PubChem | ? |
| DrugBank | |
| Chemical data | |
| Formula | C639H1006N168O196S8 |
| Mol. mass | 14434.5 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
| Colony stimulating factor 2 (granulocyte-macrophage)
| ||
|
| ||
| PDB rendering based on 2gmf | ||
| Identifiers | ||
| Symbol(s) | CSF2; GMCSF; MGC131935; MGC138897 | |
| External IDs | OMIM: 138960 MGI: 1339752 Homologene: 600 | |
| RNA expression pattern | ||
|
| ||
| Orthologs | ||
| Human | Mouse | |
| Entrez | 1437 | 12981 |
| Ensembl | ENSG00000164400 | ENSMUSG00000018916 |
| Uniprot | P04141 | Q14AD9 |
| Refseq | NM_000758 (mRNA) NP_000749 (protein) | NM_009969 (mRNA) NP_034099 (protein) |
| Location | Chr 5: 131.44 - 131.44 Mb | Chr 11: 54.09 - 54.09 Mb |
| Pubmed search | [1] | [2] |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [4] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Granulocyte-macrophage colony-stimulating factor, often abbreviated to GM-CSF, is a protein secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts.
Functions
GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exit the circulation and migrate into tissue, whereupon they mature into macrophages. It is thus part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer.
Genetics
The gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q- syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13.[1]
Glycosylation
Human granulocyte macrophage colony-stimulating factor is glycosylated in its mature form. The glycosylation sites are reported to be at amino acid residues 23 (leucine), 27 (asparagine), and 39 (glutamic acid) (see US Patent No. 5,073,627).[1]
Clinical significance
GM-CSF is also known as molgramostim or, when the protein is expressed in yeast cells, sargramostim (Leukine®).
GM-CSF is used as a medication to stimulate the production of white blood cells following chemotherapy. It has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising but GM-CSF is not presently FDA-approved for this purpose.
Leukine
Leukine is the trade name of sargramostim manufactured by Berlex Laboratories, a subsidiary of Schering AG. Its use was approved by U.S. Food and Drug Administration for acceleration of white blood cell recovery following autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma, acute lymphocytic leukemia, or Hodgkin's disease in March 1991.[1] In November 1996, the FDA also approved sargramostim for treatment of fungal infections and replenishment of white blood cells following chemotherapy.[1]
Controversy
Berlex funded a study that ran in the May 26 2005 issue of the New England Journal of Medicine which concluded that, GM-CSF did produce significantly more remissions in Crohn's disease than those who received a placebo in the study, and it also decreased disease severity and improved quality of life.[1]
The study's lead author, Joshua Korzenik of Harvard Medical School and Massachusetts General Hospital, is a paid consultant for Berlex , and co-inventor of the patent which is owned by Washington University.[1] Korzenik created a "firewall" to protect the integrity of the study, consisting of two committees to review the study results and process as well and sending trial data to outside clinicians for review.[1]
See also
References
Further reading
- Esnault S, Malter JS (2002). "GM-CSF regulation in eosinophils.". Arch. Immunol. Ther. Exp. (Warsz.) 50 (2): 121-30. PMID 12022701.
- Martinez-Moczygemba M, Huston DP (2003). "Biology of common beta receptor-signaling cytokines: IL-3, IL-5, and GM-CSF.". J. Allergy Clin. Immunol. 112 (4): 653-65; quiz 666. doi:10.1016/S0091. PMID 14564341.
- Mroczko B, Szmitkowski M (2005). "Hematopoietic cytokines as tumor markers.". Clin. Chem. Lab. Med. 42 (12): 1347-54. doi:10.1515/CCLM.2004.253. PMID 15576295.
- Hamilton JA, Anderson GP (2005). "GM-CSF Biology.". Growth Factors 22 (4): 225-31. doi:10.1080/08977190412331279881. PMID 15621725.
- Tortorella C, Simone O, Piazzolla G, et al. (2007). "Age-related impairment of GM-CSF-induced signalling in neutrophils: role of SHP-1 and SOCS proteins.". Ageing Res. Rev. 6 (2): 81-93. doi:10.1016/j.arr.2006.10.001. PMID 17142110.
- Robertson SA (2007). "GM-CSF regulation of embryo development and pregnancy.". Cytokine Growth Factor Rev. 18 (3-4): 287-98. doi:10.1016/j.cytogfr.2007.04.008. PMID 17512774.
External links
- http://www.leukine.com/ - Official Leukine web site
- MeSH Granulocyte-Macrophage+Colony-Stimulating+Factor
Cytokines, glycoproteins: colony-stimulating factors | |
|---|---|
| Numbered | Macrophage colony-stimulating factor - Granulocyte macrophage colony-stimulating factor - Granulocyte colony-stimulating factor |
| Unnumbered | Erythropoietin - Thrombopoietin - Interleukin 3 |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
